1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
3Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
4Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
5Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
Correspondence: Joseph A. Murray, MD, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. E-mail: [email protected]
Guarantor of the article: Joseph A. Murray, MD.
Specific author contributions: Study concept and design: Joseph A. Murray, S. Vincent Rajkumar, Ola Landgren and Rok Seon Choung; analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content: Rok Seon Choung, Ivo C. Ditah, Ashley M. Nadeau, Eric V. Marietta, Alberto Rubio-Tapia, Joseph A. Murray, S. Vincent Rajkumar, Ola Landgren and James E. Everhart; statistical analysis: Rok Seon Choung and Ivo C. Ditah; administrative, technical, or material support: Tricia L. Brantner and Michael J. Camilleri; study supervision: Joseph A. Murray.
Financial support: This work was partly supported by the Centers for Disease Control Contract No. M26561.
Potential competing interests: Dr Murray has received grant funding from Alba Therapeutics and Alvine Pharmaceuticals, Inc., has served on an advisory board for Alvine Pharmaceuticals, Inc., and has served as a consultant for AMAG Pharmaceuticals, Entera Health, Inc., Sonomaceuticals, LLC, BioLineRx, and GlaxoSmithKline.
